US$ 23.15
gip/glp 1-agonist tirzepatide Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction Dual and Triple Gut Peptide
Description
Source: Segal SHAPE, Segals data warehouse, 2018 to 2022 Even though many plans currently do not cover weight-loss medications, these plans are still seeing the effect that the GLP-1 medication class is having on their diabetic plan spend

doi: 10.1007/s00125-017-4350-z, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar] 144
Cureus 15, e43773

Knop FK, Brnden A, Vilsbll T

The growth hormone receptor (GHR) exon 3 polymorphism and its correlation with metabolic profiles in obese Chinese children
